Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07136701

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).

The main questions it aims to answer are:

Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.

Participants will:

Provide retrospective clinical, pathological, and metabolic data from hospital records.

Have survival and recurrence outcomes assessed through follow-up data review.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pancreatic Neuroendocine Neoplasms (pNETs)

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion criteria

  • Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Treatment and study plan

Primary outcomes

  1. Overall Survival

    Time frame: From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years

Secondary outcomes

  1. Disease-specific survival

    Time frame: From date of diagnosis until death due to PanNETs, up to 12 years

  2. Progression-free survival

    Time frame: From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.

  3. Disease-free survival

    Time frame: From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Changhao Gao, MMed

CONTACT

[email protected]

Hanxiang Zhan, MD. PhD.

CONTACT

[email protected]

+86 18560085156

Sponsors and collaborators

Lead sponsor

Qilu Hospital of Shandong University

Other

Collaborators

  • China-Japan Friendship Hospital
  • Qianfoshan Hospital
  • The Affiliated Hospital of Qingdao University

Registry information

Official study title

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Aug 22, 2025
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.